Turn Therapeutics (TTRX) Net Cash Flow (2024 - 2026)

Turn Therapeutics has reported Net Cash Flow for 3 years, with the latest figure at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 782.0% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.8 million (changed N/A YoY), and the FY2025 full-year result was $4.2 million, up 1463.03% from the prior year.
• Net Cash Flow for Q1 2026 stood at $6.2 million, up from $2.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $6.2 million in Q1 2026, with the low at $83819.0 in Q4 2024.
• Average Net Cash Flow over 3 years is $2.2 million, with a median of $1.3 million recorded in 2025.
• Year-over-year, Net Cash Flow surged 2254.3% in 2025 and surged 782.0% in 2026.
• Tracing TTRX's Net Cash Flow over 3 years: stood at $83819.0 in 2024, then surged by 2254.3% to $2.0 million in 2025, then surged by 212.89% to $6.2 million in 2026.
• The last three Net Cash Flow figures came in at $6.2 million (Q1 2026), $2.0 million (Q4 2025), and $700034.0 (Q1 2025), per Business Quant data.

Peer Comparison